lobbying_activities: 2060135

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2060135	e27f6fde-67f9-405a-9143-6c828b2ba7a7	Q4	ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)	401104361	ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)	2017	fourth_quarter	MMM	Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare	HOUSE OF REPRESENTATIVES,SENATE		143000	0	0	2018-01-11T11:29:16.237000-05:00